STRATEC maintains growth course in first quarter of 2012

- Sales of EUR 25.6 million* in Q1/2012 (+15.5%; Q1/2011: EUR 22.2 million)

- EBIT margin of 17.0%* in Q1/2012 (Q1/2011: 18.0%)

- Consolidated net income of EUR 3.4 million in Q1/2012 (+15.6%; Q1/2011: EUR 3.0m)

- Earnings per share of EUR 0.29 in Q1/2012 (+11.5%; Q1/2011: EUR 0.26)

- Publication of specific company forecast planned at the
  latest by Annual General Meeting on May 16, 2012

Birkenfeld, April 25, 2012

STRATEC Biomedical AG (Frankfurt: SBS; Prime Standard, TecDAX) today announced its figures for the period from January 1, 2012 to March 31, 2012 upon the publication of its interim report as of March 31, 2012.

 * adjusted for a one-off item due to an earnings-neutral transfer of unfinished services and prepayments received of EUR 3.3 million due to the impairment of a development project. Unadjusted sales amounted to EUR 28.8 million and the resultant EBIT margin amounted to 15.1%.

Financial performance
The significant growth in STRATEC's sales to EUR 28.8 million (+30.2%) was mainly driven by the positive performance of systems already established on the market and by systems launched onto the market in the past 24 months. This sales figure includes an earnings-neutral transfer of unfinished services and prepayments received of EUR 3.3 million due to the impairment of a development project. Excluding this one-off item, sales grew by 15.5%, and thus within the budgeted framework. The slight decline in the adjusted EBIT margin to 17% is attributable to a further significant intensification in development work for additional new system developments, a temporary weakness in gross profit in the course of a system generation change, and ramp-up activities for new analyzer systems. At EUR 3.4 million, consolidated net income was up 15.6% on the previous year's figure and corresponds to earnings per share of EUR 0.29.

The company plans to specify and extend its current forecast, which provides for average annual sales growth (CAGR) of 17% in the 2011 to 2013 financial years, with an EBIT margin of at least 19% in 2012 and 2013, at the latest by its Annual General Meeting on May 16, 2012.

Project development
Further market launches and system approvals are expected in various regions in the current and following years. To this end, further milestones have been achieved and measures continue to be taken to extend capacity within the company's existing structures.

Negotiations are currently underway for several additional new projects, and have reached advanced stages in some cases. Although it is very difficult to forecast the timing of new contracts, STRATEC expects to be able to report on further deals in the coming months.

Other developments
Our customers' forecasts continue not to be affected to any significant extent by government austerity or fiscal policy measures in the euro and dollar areas. STRATEC's business model remains largely unconnected to macroeconomic factors. To date, our talks with customers concerning new and follow-up projects have not reflected any crisis-induced change in growth expectations at STRATEC and its partners.

The company's Annual General Meeting is due to be held in Pforzheim/Germany on May 16, 2012. The Board of Management and Supervisory Board have proposed a 10% increase in the dividend to EUR 0.55 per share.

Development in staff totals
Including temporary employees, the STRATEC Group had a total of 512 employees as of March 31, 2012 (March 31, 2011: 454). Compared with December 31, 2011, the workforce has grown by a further 9 employees.

Outlook
Our indicators and forecasts, together with the company's current business performance, give reason to forecast further growth for 2012 and enable us to confirm our current guidance figures. At present, our ability to issue forecasts is temporarily impeded by external factors, such as market approval by authorities, the dates of further market launches, analyzer system generation changes, macroeconomic market influences, further consolidation in the IVD market and planned production ramp-ups for new systems. We plan to publish a more precise breakdown of our current company forecast for the 2012 to 2014 financial years at the latest by our Annual General Meeting on May 16, 2012.

Further details can be found in our Interim Report as of March 31, 2012 published at www.stratec.com > Investor Relations > IR News > Financial Reports.

About STRATEC
STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies.

Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the TecDAX select index of the German Stock Exchange.

Further information can be obtained from:
STRATEC Biomedical AG
André Loy, Investor Relations
Gewerbestr. 37, 75217 Birkenfeld
Germany
Tel: +49 7082 7916-190
Fax: +49 7082 7916-999
ir@stratec.com
www.stratec.com